Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

A study conducted at the Federal University of São Paulo (UNIFESP) in Brazil has concluded that the use of monochromatic ...

China’s medicines regulator has granted the nod for the treatment of people with chronic inflammatory demyelinating ...

The Amsterdam-based firm markets Vyvgart, a prescription medicine indicated for neurological conditions, generalized ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

KORU Medical Systems (NASDAQ:KRMD – Get Free Report) will release its earnings data after the market closes on Wednesday, ...

Zai Lab (ZLAB) and Argenx (ARGX) announced that China’s National Medical Products Administration, or NMPA, approved the supplemental ...